Regeneron Pharmaceuticals Inc stock (US7739031091): shares steady as EMA accepts eye drug filing and Wolfe trims target

Regeneron Pharmaceuticals shares trade broadly stable in the United States after the European Medicines Agency accepted review of the company’s otarminigene zoparvovec application while Wolfe Research adjusted its price target, keeping focus on the biotech’s late-stage pipeline.

Regeneron Pharmaceuticals shares on Nasdaq under the ticker REGN traded broadly unchanged in recent sessions, after the New York-based biotech reported that the European Medicines Agency (EMA) accepted for review the marketing authorization application for its gene therapy candidate otarminigene zoparvovec in inherited retinal disease, while Wolfe Research modestly lowered its price target but maintained an Outperform rating, underscoring continuing confidence in the company’s United States-listed equity and late-stage pipeline according to Reuters as of 05/31/2026 and Wolfe Research commentary cited by InsiderMonkey as of 05/31/2026.

The stock last closed around the mid-USD 900 range on Nasdaq on 05/31/2026, compared with Wolfe Research’s revised target of USD 860, as analyst Alexandria Hammond trimmed the valuation from USD 900 but reiterated an Outperform stance, according to Wolfe Research data referenced by InsiderMonkey as of 05/31/2026, highlighting that the adjustment reflects updated modeling rather than a fundamental shift in view on Regeneron’s core franchises in the United States.

The EMA’s validation of the otarminigene zoparvovec filing means the application has successfully passed the agency’s administrative check and can proceed to a full scientific review, a procedural but important milestone for the program targeting a form of inherited retinal disease that adds to Regeneron’s established ophthalmology franchise built around Eylea, according to company statements summarized by Reuters as of 05/31/2026.

The shares remain an important component of the U.S. biotechnology universe, with Regeneron continuing to trade on Nasdaq and contributing to various thematic indices such as the Solactive ISS ESG US Tech 100 Index where it holds a small weight, according to data from Solactive as of 05/30/2026, keeping the United States firmly at the center of the investment case.

For investors in Germany, Regeneron also trades on off-exchange platforms such as Tradegate in euros, providing an additional access point for European retail investors alongside its primary United States listing on Nasdaq.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: REGN
• Sector/industry: Biotechnology and pharmaceuticals
• Headquarters/country: Tarrytown, United States
• Core markets: United States, Europe
• Key revenue drivers: Ophthalmology, immunology and oncology therapies
• Home exchange/listing venue: Nasdaq (REGN)
• Trading currency: USD

Regeneron Pharmaceuticals Inc: core business model

Regeneron focuses on discovering and developing monoclonal antibodies and related biologic medicines, with sales largely generated by ophthalmology drugs like Eylea and immunology products such as Dupixent, alongside an expanding oncology portfolio co-developed with partners.

What banks and research houses say about Regeneron Pharmaceuticals Inc

Wolfe Research’s decision to trim its price target on Regeneron to USD 860 from USD 900 while keeping an Outperform rating, as noted by analyst Alexandria Hammond in a research update referenced by InsiderMonkey on 05/31/2026, illustrates how some U.S. sell-side analysts are fine-tuning their models around the company’s pipeline timelines and competitive landscape rather than materially changing their view of the stock.

Beyond Wolfe Research, Regeneron remains widely followed by major Wall Street institutions including JPMorgan, Goldman Sachs and Morgan Stanley, which typically focus on the durability of Eylea revenue, the growth runway for Dupixent in multiple indications, and the potential contribution from newer oncology and gene therapy assets such as otarminigene zoparvovec as they assess the outlook for the U.S.-listed shares.

Conclusion

The latest combination of EMA review acceptance for otarminigene zoparvovec and Wolfe Research’s revised price target keeps attention on how Regeneron balances its mature ophthalmology and immunology assets with newer gene therapy and oncology programs.

With the stock continuing to trade actively on Nasdaq in the United States and remaining a component of thematic indices, the coming quarters will likely see investors track regulatory milestones in Europe alongside evolving bank research commentary when assessing the company’s equity story.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.